Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study
| العنوان: | Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study |
|---|---|
| المؤلفون: | Theresa Hippchen, Adeline Lim, Jessica Seeßle, Marietta Kirchner, Barbara Müller, Julia Simon, Uta Merle, Tim Waterboer |
| المصدر: | Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |
| بيانات النشر: | Oxford University Press (OUP), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Microbiology (medical), medicine.medical_specialty, ANA titers, Coronavirus disease 2019 (COVID-19), Anti-nuclear antibody, business.industry, life quality, Persistence (computer science), AcademicSubjects/MED00290, Infectious Diseases, Quality of life, Internal medicine, Cohort, Major Article, Etiology, coronavirus disease 2019 (COVID-19), Medicine, long COVID, business, Prospective cohort study, Neurocognitive |
| الوصف: | Background Long COVID is defined as the persistence of symptoms beyond 3 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To better understand the long-term course and etiology of symptoms we analyzed a cohort of patients with COVID-19 prospectively. Methods Patients were included at 5 months after acute COVID-19 in this prospective, noninterventional, follow-up study. Patients followed until 12 months after COVID-19 symptom onset (n = 96; 32.3% hospitalized, 55.2% females) were included in this analysis of symptoms, quality of life (based on an SF-12 survey), laboratory parameters including antinuclear antibodies (ANAs), and SARS-CoV-2 antibody levels. Results At month 12, only 22.9% of patients were completely free of symptoms and the most frequent symptoms were reduced exercise capacity (56.3%), fatigue (53.1%), dyspnea (37.5%), and problems with concentration (39.6%), finding words (32.3%), and sleeping (26.0%). Females showed significantly more neurocognitive symptoms than males. ANA titers were ≥1:160 in 43.6% of patients at 12 months post–COVID-19 symptom onset, and neurocognitive symptom frequency was significantly higher in the group with an ANA titer ≥1:160 versus Neurocognitive long-COVID symptoms can persist at least for 1 year after acute COVID-19 and reduce life quality significantly. Several neurocognitive symptoms were associated with ANA titer elevations. This may indicate autoimmunity as a cofactor in the etiology of long COVID. |
| تدمد: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciab611 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e40843462b7baa30a6a842ffc5c513 https://doi.org/10.1093/cid/ciab611 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b3e40843462b7baa30a6a842ffc5c513 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15376591 10584838 |
|---|---|
| DOI: | 10.1093/cid/ciab611 |